nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Azathioprine—multiple sclerosis	0.803	1	CbGbCtD
Deferoxamine—Myalgia—Mitoxantrone—multiple sclerosis	0.000364	0.00185	CcSEcCtD
Deferoxamine—Arthralgia—Mitoxantrone—multiple sclerosis	0.000364	0.00185	CcSEcCtD
Deferoxamine—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000363	0.00184	CcSEcCtD
Deferoxamine—Diarrhoea—Cladribine—multiple sclerosis	0.000363	0.00184	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisolone—multiple sclerosis	0.00036	0.00183	CcSEcCtD
Deferoxamine—Visual impairment—Methylprednisolone—multiple sclerosis	0.000356	0.00181	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000353	0.00179	CcSEcCtD
Deferoxamine—Dizziness—Cladribine—multiple sclerosis	0.000351	0.00178	CcSEcCtD
Deferoxamine—Erythema—Prednisolone—multiple sclerosis	0.000351	0.00178	CcSEcCtD
Deferoxamine—Oedema—Mitoxantrone—multiple sclerosis	0.000349	0.00177	CcSEcCtD
Deferoxamine—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000349	0.00177	CcSEcCtD
Deferoxamine—Infection—Mitoxantrone—multiple sclerosis	0.000347	0.00176	CcSEcCtD
Deferoxamine—Eye disorder—Methylprednisolone—multiple sclerosis	0.000346	0.00175	CcSEcCtD
Deferoxamine—Shock—Mitoxantrone—multiple sclerosis	0.000343	0.00174	CcSEcCtD
Deferoxamine—Bradycardia—Dexamethasone—multiple sclerosis	0.000342	0.00174	CcSEcCtD
Deferoxamine—Bradycardia—Betamethasone—multiple sclerosis	0.000342	0.00174	CcSEcCtD
Deferoxamine—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000342	0.00173	CcSEcCtD
Deferoxamine—Abdominal pain—Azathioprine—multiple sclerosis	0.000341	0.00173	CcSEcCtD
Deferoxamine—Body temperature increased—Azathioprine—multiple sclerosis	0.000341	0.00173	CcSEcCtD
Deferoxamine—Tachycardia—Mitoxantrone—multiple sclerosis	0.000341	0.00173	CcSEcCtD
Deferoxamine—Skin disorder—Mitoxantrone—multiple sclerosis	0.000339	0.00172	CcSEcCtD
Deferoxamine—Vomiting—Cladribine—multiple sclerosis	0.000338	0.00171	CcSEcCtD
Deferoxamine—Angiopathy—Methylprednisolone—multiple sclerosis	0.000336	0.0017	CcSEcCtD
Deferoxamine—Hallucination—Dexamethasone—multiple sclerosis	0.000335	0.0017	CcSEcCtD
Deferoxamine—Hallucination—Betamethasone—multiple sclerosis	0.000335	0.0017	CcSEcCtD
Deferoxamine—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000334	0.00169	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000333	0.00169	CcSEcCtD
Deferoxamine—Headache—Cladribine—multiple sclerosis	0.000333	0.00169	CcSEcCtD
Deferoxamine—Arrhythmia—Triamcinolone—multiple sclerosis	0.000331	0.00168	CcSEcCtD
Deferoxamine—Vision blurred—Prednisolone—multiple sclerosis	0.000331	0.00168	CcSEcCtD
Deferoxamine—Arrhythmia—Methylprednisolone—multiple sclerosis	0.00033	0.00168	CcSEcCtD
Deferoxamine—Hypotension—Mitoxantrone—multiple sclerosis	0.000326	0.00165	CcSEcCtD
Deferoxamine—Visual impairment—Betamethasone—multiple sclerosis	0.000324	0.00164	CcSEcCtD
Deferoxamine—Visual impairment—Dexamethasone—multiple sclerosis	0.000324	0.00164	CcSEcCtD
Deferoxamine—Erythema—Triamcinolone—multiple sclerosis	0.000323	0.00164	CcSEcCtD
Deferoxamine—Erythema—Methylprednisolone—multiple sclerosis	0.000322	0.00163	CcSEcCtD
Deferoxamine—Angioedema—Prednisolone—multiple sclerosis	0.000321	0.00163	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisone—multiple sclerosis	0.00032	0.00162	CcSEcCtD
Deferoxamine—Hypersensitivity—Azathioprine—multiple sclerosis	0.000318	0.00161	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000318	0.00161	CcSEcCtD
Deferoxamine—Nausea—Cladribine—multiple sclerosis	0.000315	0.0016	CcSEcCtD
Deferoxamine—Eye disorder—Betamethasone—multiple sclerosis	0.000314	0.00159	CcSEcCtD
Deferoxamine—Eye disorder—Dexamethasone—multiple sclerosis	0.000314	0.00159	CcSEcCtD
Deferoxamine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000313	0.00159	CcSEcCtD
Deferoxamine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000311	0.00158	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—multiple sclerosis	0.000306	0.00155	CcSEcCtD
Deferoxamine—Angiopathy—Betamethasone—multiple sclerosis	0.000305	0.00155	CcSEcCtD
Deferoxamine—Angiopathy—Dexamethasone—multiple sclerosis	0.000305	0.00155	CcSEcCtD
Deferoxamine—Convulsion—Prednisolone—multiple sclerosis	0.000304	0.00154	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—multiple sclerosis	0.000303	0.00154	CcSEcCtD
Deferoxamine—Arrhythmia—Dexamethasone—multiple sclerosis	0.0003	0.00152	CcSEcCtD
Deferoxamine—Arrhythmia—Betamethasone—multiple sclerosis	0.0003	0.00152	CcSEcCtD
Deferoxamine—Pain—Mitoxantrone—multiple sclerosis	0.000298	0.00151	CcSEcCtD
Deferoxamine—Bradycardia—Prednisone—multiple sclerosis	0.000298	0.00151	CcSEcCtD
Deferoxamine—Diarrhoea—Azathioprine—multiple sclerosis	0.000295	0.0015	CcSEcCtD
Deferoxamine—Angioedema—Triamcinolone—multiple sclerosis	0.000295	0.0015	CcSEcCtD
Deferoxamine—Angioedema—Methylprednisolone—multiple sclerosis	0.000294	0.00149	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000293	0.00149	CcSEcCtD
Deferoxamine—Erythema—Dexamethasone—multiple sclerosis	0.000293	0.00148	CcSEcCtD
Deferoxamine—Erythema—Betamethasone—multiple sclerosis	0.000293	0.00148	CcSEcCtD
Deferoxamine—Hallucination—Prednisone—multiple sclerosis	0.000291	0.00148	CcSEcCtD
Deferoxamine—Connective tissue disorder—Prednisone—multiple sclerosis	0.000288	0.00146	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000286	0.00145	CcSEcCtD
Deferoxamine—Oedema—Prednisolone—multiple sclerosis	0.000286	0.00145	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—multiple sclerosis	0.000286	0.00145	CcSEcCtD
Deferoxamine—Dizziness—Azathioprine—multiple sclerosis	0.000286	0.00145	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000285	0.00145	CcSEcCtD
Deferoxamine—Shock—Prednisolone—multiple sclerosis	0.000282	0.00143	CcSEcCtD
Deferoxamine—Convulsion—Triamcinolone—multiple sclerosis	0.00028	0.00142	CcSEcCtD
Deferoxamine—Tachycardia—Prednisolone—multiple sclerosis	0.000279	0.00142	CcSEcCtD
Deferoxamine—Convulsion—Methylprednisolone—multiple sclerosis	0.000279	0.00141	CcSEcCtD
Deferoxamine—Urticaria—Mitoxantrone—multiple sclerosis	0.000277	0.00141	CcSEcCtD
Deferoxamine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000276	0.0014	CcSEcCtD
Deferoxamine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000276	0.0014	CcSEcCtD
Deferoxamine—Myalgia—Triamcinolone—multiple sclerosis	0.000275	0.00139	CcSEcCtD
Deferoxamine—Vomiting—Azathioprine—multiple sclerosis	0.000275	0.00139	CcSEcCtD
Deferoxamine—Arthralgia—Methylprednisolone—multiple sclerosis	0.000274	0.00139	CcSEcCtD
Deferoxamine—Myalgia—Methylprednisolone—multiple sclerosis	0.000274	0.00139	CcSEcCtD
Deferoxamine—Eye disorder—Prednisone—multiple sclerosis	0.000274	0.00139	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—multiple sclerosis	0.000273	0.00138	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—multiple sclerosis	0.000273	0.00138	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000272	0.00138	CcSEcCtD
Deferoxamine—Headache—Azathioprine—multiple sclerosis	0.000271	0.00137	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—multiple sclerosis	0.000268	0.00136	CcSEcCtD
Deferoxamine—Angioedema—Dexamethasone—multiple sclerosis	0.000268	0.00136	CcSEcCtD
Deferoxamine—Angioedema—Betamethasone—multiple sclerosis	0.000268	0.00136	CcSEcCtD
Deferoxamine—Angiopathy—Prednisone—multiple sclerosis	0.000266	0.00135	CcSEcCtD
Deferoxamine—Immune system disorder—Prednisone—multiple sclerosis	0.000265	0.00134	CcSEcCtD
Deferoxamine—Oedema—Triamcinolone—multiple sclerosis	0.000263	0.00134	CcSEcCtD
Deferoxamine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000263	0.00134	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000263	0.00133	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisone—multiple sclerosis	0.000262	0.00133	CcSEcCtD
Deferoxamine—Infection—Triamcinolone—multiple sclerosis	0.000262	0.00133	CcSEcCtD
Deferoxamine—Infection—Methylprednisolone—multiple sclerosis	0.000261	0.00132	CcSEcCtD
Deferoxamine—Shock—Triamcinolone—multiple sclerosis	0.000259	0.00131	CcSEcCtD
Deferoxamine—Shock—Methylprednisolone—multiple sclerosis	0.000259	0.00131	CcSEcCtD
Deferoxamine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000258	0.00131	CcSEcCtD
Deferoxamine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000257	0.0013	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisolone—multiple sclerosis	0.000257	0.0013	CcSEcCtD
Deferoxamine—Tachycardia—Triamcinolone—multiple sclerosis	0.000257	0.0013	CcSEcCtD
Deferoxamine—Nausea—Azathioprine—multiple sclerosis	0.000256	0.0013	CcSEcCtD
Deferoxamine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000256	0.0013	CcSEcCtD
Deferoxamine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000255	0.00129	CcSEcCtD
Deferoxamine—Erythema—Prednisone—multiple sclerosis	0.000255	0.00129	CcSEcCtD
Deferoxamine—Convulsion—Dexamethasone—multiple sclerosis	0.000254	0.00129	CcSEcCtD
Deferoxamine—Convulsion—Betamethasone—multiple sclerosis	0.000254	0.00129	CcSEcCtD
Deferoxamine—Myalgia—Dexamethasone—multiple sclerosis	0.000249	0.00126	CcSEcCtD
Deferoxamine—Myalgia—Betamethasone—multiple sclerosis	0.000249	0.00126	CcSEcCtD
Deferoxamine—Hypotension—Methylprednisolone—multiple sclerosis	0.000246	0.00125	CcSEcCtD
Deferoxamine—Pain—Prednisolone—multiple sclerosis	0.000245	0.00124	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000242	0.00123	CcSEcCtD
Deferoxamine—Vision blurred—Prednisone—multiple sclerosis	0.00024	0.00122	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—multiple sclerosis	0.00024	0.00122	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00024	0.00122	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000239	0.00121	CcSEcCtD
Deferoxamine—Oedema—Dexamethasone—multiple sclerosis	0.000239	0.00121	CcSEcCtD
Deferoxamine—Oedema—Betamethasone—multiple sclerosis	0.000239	0.00121	CcSEcCtD
Deferoxamine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000239	0.00121	CcSEcCtD
Deferoxamine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000239	0.00121	CcSEcCtD
Deferoxamine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000239	0.00121	CcSEcCtD
Deferoxamine—Infection—Betamethasone—multiple sclerosis	0.000237	0.0012	CcSEcCtD
Deferoxamine—Infection—Dexamethasone—multiple sclerosis	0.000237	0.0012	CcSEcCtD
Deferoxamine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000236	0.0012	CcSEcCtD
Deferoxamine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000236	0.0012	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—multiple sclerosis	0.000236	0.0012	CcSEcCtD
Deferoxamine—Shock—Dexamethasone—multiple sclerosis	0.000235	0.00119	CcSEcCtD
Deferoxamine—Shock—Betamethasone—multiple sclerosis	0.000235	0.00119	CcSEcCtD
Deferoxamine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000235	0.00119	CcSEcCtD
Deferoxamine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000234	0.00119	CcSEcCtD
Deferoxamine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000234	0.00119	CcSEcCtD
Deferoxamine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000234	0.00119	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000234	0.00119	CcSEcCtD
Deferoxamine—Tachycardia—Dexamethasone—multiple sclerosis	0.000233	0.00118	CcSEcCtD
Deferoxamine—Tachycardia—Betamethasone—multiple sclerosis	0.000233	0.00118	CcSEcCtD
Deferoxamine—Angioedema—Prednisone—multiple sclerosis	0.000233	0.00118	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—multiple sclerosis	0.000229	0.00116	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—multiple sclerosis	0.000228	0.00116	CcSEcCtD
Deferoxamine—Urticaria—Prednisolone—multiple sclerosis	0.000227	0.00115	CcSEcCtD
Deferoxamine—Pain—Triamcinolone—multiple sclerosis	0.000225	0.00114	CcSEcCtD
Deferoxamine—Hypotension—Dexamethasone—multiple sclerosis	0.000223	0.00113	CcSEcCtD
Deferoxamine—Hypotension—Betamethasone—multiple sclerosis	0.000223	0.00113	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—multiple sclerosis	0.000222	0.00113	CcSEcCtD
Deferoxamine—Vomiting—Mitoxantrone—multiple sclerosis	0.000222	0.00113	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—multiple sclerosis	0.000221	0.00112	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—multiple sclerosis	0.000221	0.00112	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000221	0.00112	CcSEcCtD
Deferoxamine—Headache—Mitoxantrone—multiple sclerosis	0.000219	0.00111	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000218	0.0011	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000218	0.0011	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—multiple sclerosis	0.000217	0.0011	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—multiple sclerosis	0.000217	0.0011	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000216	0.00109	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000215	0.00109	CcSEcCtD
Deferoxamine—Paraesthesia—Betamethasone—multiple sclerosis	0.000215	0.00109	CcSEcCtD
Deferoxamine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000215	0.00109	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—multiple sclerosis	0.000213	0.00108	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000211	0.00107	CcSEcCtD
Deferoxamine—Urticaria—Triamcinolone—multiple sclerosis	0.000209	0.00106	CcSEcCtD
Deferoxamine—Urticaria—Methylprednisolone—multiple sclerosis	0.000209	0.00106	CcSEcCtD
Deferoxamine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000208	0.00106	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000208	0.00106	CcSEcCtD
Deferoxamine—Oedema—Prednisone—multiple sclerosis	0.000208	0.00106	CcSEcCtD
Deferoxamine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000208	0.00105	CcSEcCtD
Deferoxamine—Nausea—Mitoxantrone—multiple sclerosis	0.000207	0.00105	CcSEcCtD
Deferoxamine—Infection—Prednisone—multiple sclerosis	0.000207	0.00105	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000206	0.00105	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000206	0.00105	CcSEcCtD
Deferoxamine—Shock—Prednisone—multiple sclerosis	0.000205	0.00104	CcSEcCtD
Deferoxamine—Pain—Dexamethasone—multiple sclerosis	0.000204	0.00104	CcSEcCtD
Deferoxamine—Pain—Betamethasone—multiple sclerosis	0.000204	0.00104	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—multiple sclerosis	0.000204	0.00103	CcSEcCtD
Deferoxamine—Tachycardia—Prednisone—multiple sclerosis	0.000203	0.00103	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—multiple sclerosis	0.000202	0.00103	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—multiple sclerosis	0.000201	0.00102	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000195	0.000991	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000195	0.000991	CcSEcCtD
Deferoxamine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000194	0.000984	CcSEcCtD
Deferoxamine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000194	0.000982	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—multiple sclerosis	0.000191	0.000967	CcSEcCtD
Deferoxamine—Urticaria—Dexamethasone—multiple sclerosis	0.00019	0.000963	CcSEcCtD
Deferoxamine—Urticaria—Betamethasone—multiple sclerosis	0.00019	0.000963	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00019	0.000962	CcSEcCtD
Deferoxamine—Dizziness—Prednisolone—multiple sclerosis	0.000189	0.00096	CcSEcCtD
Deferoxamine—Abdominal pain—Betamethasone—multiple sclerosis	0.000189	0.000958	CcSEcCtD
Deferoxamine—Body temperature increased—Betamethasone—multiple sclerosis	0.000189	0.000958	CcSEcCtD
Deferoxamine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000189	0.000958	CcSEcCtD
Deferoxamine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000189	0.000958	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisone—multiple sclerosis	0.000187	0.000948	CcSEcCtD
Deferoxamine—Pruritus—Triamcinolone—multiple sclerosis	0.000186	0.000945	CcSEcCtD
Deferoxamine—Pruritus—Methylprednisolone—multiple sclerosis	0.000186	0.000943	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—multiple sclerosis	0.000185	0.000936	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—multiple sclerosis	0.000181	0.00092	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—multiple sclerosis	0.000181	0.00092	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00018	0.000914	CcSEcCtD
Deferoxamine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00018	0.000912	CcSEcCtD
Deferoxamine—Headache—Prednisolone—multiple sclerosis	0.000179	0.00091	CcSEcCtD
Deferoxamine—Dizziness—Triamcinolone—multiple sclerosis	0.000174	0.000883	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000174	0.000882	CcSEcCtD
Deferoxamine—Dizziness—Methylprednisolone—multiple sclerosis	0.000174	0.000881	CcSEcCtD
Deferoxamine—Infection—Methotrexate—multiple sclerosis	0.000173	0.000876	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000171	0.000865	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.00017	0.000864	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00017	0.000863	CcSEcCtD
Deferoxamine—Nausea—Prednisolone—multiple sclerosis	0.00017	0.000863	CcSEcCtD
Deferoxamine—Pruritus—Dexamethasone—multiple sclerosis	0.000169	0.000857	CcSEcCtD
Deferoxamine—Pruritus—Betamethasone—multiple sclerosis	0.000169	0.000857	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—multiple sclerosis	0.000169	0.000857	CcSEcCtD
Deferoxamine—Vomiting—Triamcinolone—multiple sclerosis	0.000167	0.000849	CcSEcCtD
Deferoxamine—Vomiting—Methylprednisolone—multiple sclerosis	0.000167	0.000847	CcSEcCtD
Deferoxamine—Urticaria—Prednisone—multiple sclerosis	0.000165	0.000838	CcSEcCtD
Deferoxamine—Headache—Triamcinolone—multiple sclerosis	0.000165	0.000837	CcSEcCtD
Deferoxamine—Headache—Methylprednisolone—multiple sclerosis	0.000165	0.000835	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—multiple sclerosis	0.000165	0.000834	CcSEcCtD
Deferoxamine—Abdominal pain—Prednisone—multiple sclerosis	0.000165	0.000834	CcSEcCtD
Deferoxamine—Diarrhoea—Betamethasone—multiple sclerosis	0.000163	0.000829	CcSEcCtD
Deferoxamine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000163	0.000829	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—multiple sclerosis	0.000163	0.000824	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000158	0.000804	CcSEcCtD
Deferoxamine—Dizziness—Dexamethasone—multiple sclerosis	0.000158	0.000801	CcSEcCtD
Deferoxamine—Dizziness—Betamethasone—multiple sclerosis	0.000158	0.000801	CcSEcCtD
Deferoxamine—Nausea—Triamcinolone—multiple sclerosis	0.000156	0.000793	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—multiple sclerosis	0.000156	0.000792	CcSEcCtD
Deferoxamine—Nausea—Methylprednisolone—multiple sclerosis	0.000156	0.000792	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—multiple sclerosis	0.000155	0.000786	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisone—multiple sclerosis	0.000153	0.000778	CcSEcCtD
Deferoxamine—Vomiting—Dexamethasone—multiple sclerosis	0.000152	0.000771	CcSEcCtD
Deferoxamine—Vomiting—Betamethasone—multiple sclerosis	0.000152	0.000771	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00015	0.000761	CcSEcCtD
Deferoxamine—Headache—Betamethasone—multiple sclerosis	0.00015	0.000759	CcSEcCtD
Deferoxamine—Headache—Dexamethasone—multiple sclerosis	0.00015	0.000759	CcSEcCtD
Deferoxamine—Pain—Methotrexate—multiple sclerosis	0.000149	0.000754	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—multiple sclerosis	0.000147	0.000747	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—multiple sclerosis	0.000142	0.000722	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000142	0.000721	CcSEcCtD
Deferoxamine—Nausea—Dexamethasone—multiple sclerosis	0.000142	0.00072	CcSEcCtD
Deferoxamine—Nausea—Betamethasone—multiple sclerosis	0.000142	0.00072	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—multiple sclerosis	0.000138	0.000701	CcSEcCtD
Deferoxamine—Dizziness—Prednisone—multiple sclerosis	0.000138	0.000698	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—multiple sclerosis	0.000137	0.000697	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—multiple sclerosis	0.000137	0.000697	CcSEcCtD
Deferoxamine—Vomiting—Prednisone—multiple sclerosis	0.000132	0.000671	CcSEcCtD
Deferoxamine—Headache—Prednisone—multiple sclerosis	0.00013	0.000661	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000128	0.00065	CcSEcCtD
Deferoxamine—Nausea—Prednisone—multiple sclerosis	0.000124	0.000627	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—multiple sclerosis	0.000123	0.000624	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—multiple sclerosis	0.000119	0.000603	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—multiple sclerosis	0.000115	0.000583	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—multiple sclerosis	0.000111	0.000561	CcSEcCtD
Deferoxamine—Headache—Methotrexate—multiple sclerosis	0.000109	0.000553	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—multiple sclerosis	0.000103	0.000524	CcSEcCtD
